Search Result

Results for "

Constipation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Apical Sodium-Dependent Bile Acid Transporter (2) Apoptosis (2) Autophagy (2) Bacterial (2) Chloride Channel (2) Endogenous Metabolite (1) GHSR (1) GLUT (1) Guanylate Cyclase (4) Interleukin Related (1) Isotope-Labeled Compounds (1) mAChR (1) Motilin Receptor (1) Opioid Receptor (6) TNF Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (4) Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (16) Neurological Disease (11)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N7104

Lactitol

D-Lactitol
Bacterial Endocrinology

Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research .

Lactitol D-Lactitol	Bacterial	Endocrinology
Lactitol (D-Lactitol), a nonabsorbable disaccharide, has the potential for constipation research .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Neurological Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-144401

DS-3801b	Motilin Receptor	Metabolic Disease
DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation .

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease
Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .

HY-128361

SLC26A3-IN-3

GLUT Inflammation/Immunology

SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC₅₀: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis .

SLC26A3-IN-3	GLUT	Inflammation/Immunology
SLC26A3-IN-3 (compound 4az) is a SLC26A3 inhibitor (IC₅₀: 40 nM). SLC26A3-IN-3 can be used for research of constipation, cystic fibrosis .

HY-144606

Mu opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Mu opioid receptor antagonist 1 (compound 19) is a selective and orally active μ opioid receptor (MOR) ligand with an K_i value of 0.58 nM and an EC₅₀ of 1.15 nM. Orally administrating with Mu opioid receptor antagonist 1 increases intestinal motility during morphine-induced constipation. Mu opioid receptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .

HY-19627

Naldemedine S-297995	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-19627A

Naldemedine tosylate S-297995 tosylate	Opioid Receptor	Neurological Disease Metabolic Disease
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (K_i=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL ^pro encoded by SARS-CoV2 genome .

HY-15790A

Elobixibat hydrate A 3309 hydrate; AZD 7806 hydrate	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC₅₀ values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .

HY-108741A

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

HY-111232

GSK894281	GHSR	Metabolic Disease
GSK894281 is an orally active and highly potent ghrelin receptor full agonist with a pEC₅₀ of <4.9 at the human motilin receptor. GSK894281 effectively enters the CNS. GSK894281 has the potential for constipation or to assist in emptying the colon prior to colonoscopy or colon surgery research .

HY-17584

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

HY-14151

Prucalopride 2 Publications Verification	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-B0679S

Lubiprostone-d7 RU-0211-d₇; SPI-0211-d₇	Chloride Channel	Metabolic Disease
Lubiprostone-d₇ (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].

HY-15790

Elobixibat A 3309; AZD 7806	Apical Sodium-Dependent Bile Acid Transporter Interleukin Related TNF Receptor	Metabolic Disease Inflammation/Immunology
Elobixibat (A 3309; AZD 7806) is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor, with an IC₅₀ value of 0.53 nM (human IBAT ), 0.13 nM (mouse IBAT), 5.8 nM (canine IBAT). Elobixibat lowers LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .

HY-B1172

Lactulose 4-O-β-D-Galactopyranosyl-D-fructose	Endogenous Metabolite Bacterial	Others
Lactulose (4-O-β-D-Galactopyranosyl-D-fructose) is a poorly absorbed sugar that can be used to study constipation and hepatic encephalopathy. The drug generally begins to take effect 8 to 12 hours after administration, but it may take two days to improve constipation.

HY-A0118AS

Naloxegol-d5 oxalate	Isotope-Labeled Compounds Opioid Receptor	Neurological Disease
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

HY-B0679

Lubiprostone 1 Publications Verification RU-0211; SPI-0211	Chloride Channel	Metabolic Disease
Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.

HY-14152

Prucalopride hydrochloride	5-HT Receptor	Cancer
Prucalopride hydrochloride is an orally active, selective and specific 5-HT4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride hydrochloride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride hydrochloride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride hydrochloride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-P3282

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

HY-101907

ASP7663 1 Publications Verification	TRP Channel	Neurological Disease
ASP7663 is an orally active and selective TRPA1 agonist. ASP7663 exerts both anti-constipation and anti-abdominal pain actions .

HY-133860

Chrysoobtusin	Others	Others
Chrysoobtusin is an anthraquinone derivative isolated from Semen Cassiae. Semen Cassiae has long been used to protect liver, brighten eyes, and relieve constipation .

HY-B2134

Casanthranol	Others	Metabolic Disease
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions .

HY-14147

Renzapride BRL 24924	5-HT Receptor	Metabolic Disease
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist . Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-10457A

Velusetrag hydrochloride TD-5108 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) hydrochloride is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT₄R), with a pK_i of 7.7. Velusetrag hydrochloride exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag hydrochloride can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-10457

Velusetrag TD-5108	5-HT Receptor	Neurological Disease Metabolic Disease
Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT₄ receptor (5-HT4R), with a pK_i of 7.7. Velusetrag exhibits no affinity (K_i>10 μM) for 5-HT_2A and 5-HT_2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease .

HY-121826

Naronapride ATI-7505	5-HT Receptor	Metabolic Disease Inflammation/Immunology
Naronapride (ATI-7505) is a potent prokinetic 5-HT₄ receptor agonist. Naronapride can be used for gastrointestinal diseases research .

HY-17638

Mizagliflozin 2 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-14147A

(S)-Renzapride (S)-BRL 24924	5-HT Receptor	Metabolic Disease
(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT₄ receptor agonist with a K_i value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study .

HY-B1132

Clidinium bromide Ro 2-3773	mAChR	Neurological Disease
Clidinium bromide is a quaternary amine antimuscarinic agent. Clidinium bromide may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines in vivo .

HY-108741

Plecanatide	Guanylate Cyclase	Inflammation/Immunology
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .

HY-12694

Prucalopride succinate 2 Publications Verification R-108512	5-HT Receptor Apoptosis Autophagy	Metabolic Disease Cancer
Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

Plecanatide acetate	Guanylate Cyclase	Inflammation/Immunology
Plecanatide acetate, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide acetate can be used for the research of chronic idiopathic constipation, and it also shows anti-inflammatory activity in models of murine colitis .

Linaclotide 2 Publications Verification	Guanylate Cyclase	Cancer
Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.

MM 419447	Guanylate Cyclase	Metabolic Disease
MM 419447, a linaclotide metabolite, is a guanylate cyclase-C agonist. MM 419447 has the potential for the research of the irritable bowel syndrome with constipation (IBS-C) .

Plecanatide	Guanylate Cyclase	Inflammation/Immunology
Plecanatide, an analogue of Uroguanylin, is an orally active guanylate cyclase-C (GC-C) receptor agonist. Plecanatide activates GC-C receptors to stimulate cGMP synthesis with an EC₅₀ of 190 nM in T84 cells assay. Plecanatide shows anti-inflammatory activity in models of murine colitis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1172

Lactulose 4-O-β-D-Galactopyranosyl-D-fructose	Structural Classification Polysaccharides Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite Bacterial
Lactulose (4-O-β-D-Galactopyranosyl-D-fructose) is a poorly absorbed sugar that can be used to study constipation and hepatic encephalopathy. The drug generally begins to take effect 8 to 12 hours after administration, but it may take two days to improve constipation.

HY-133860

Chrysoobtusin	Seeds of Cassia tora Linn. Structural Classification Classification of Application Fields Source classification Plants Quinones other families Leguminosae Anthraquinones Other Diseases Phenols Polyphenols Disease Research Fields	Others
Chrysoobtusin is an anthraquinone derivative isolated from Semen Cassiae. Semen Cassiae has long been used to protect liver, brighten eyes, and relieve constipation .

HY-B2134

Casanthranol	Natural Products other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields	Others
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions .

Cat. No.	Product Name	Chemical Structure

HY-B0679S

Lubiprostone-d7
Lubiprostone-d₇ (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation[1][2].

HY-A0118AS

Naloxegol-d5 oxalate
Naloxegol-d₅ (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Constipation

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products